Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 28.04.2025 3 AJR Am J Roentgenol 1 Am J Pathol 1 Ann Surg Oncol 1 Arch Bronconeumol 6 BMC Cancer 1 Cancer 1 Chest 1 Clin Cancer Res 1 Clin Exp Metastasis 1 Clin Lung Cancer 3 Eur J Cancer 2 Int J Cancer 1 J Cancer Res Clin Oncol 2 J Thorac Oncol 4 Lung Cancer 1 N Engl J Med 1 Oncogene 1 PLoS One 1 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. ESCALON JG
   Beyond the AJR: Adherence to Annual Lung Cancer Screening and Rates of Cancer Diagnosis.
   AJR Am J Roentgenol. 2025 Apr 23. doi: 10.2214/AJR.25.33107.
   PubMed        
   
   
2. CHELALA L
   Lung-RADS: A Powerful Tool in the Optimization of Lung Cancer Screening.
   AJR Am J Roentgenol. 2025 Apr 23. doi: 10.2214/AJR.25.33108.
   PubMed        
   
   
3. ZUCKER EJ
   Practical Utilization of Artificial Intelligence Algorithms for Low-Dose Lung Cancer Screening CT-Finding the Sweet Spot.
   AJR Am J Roentgenol. 2025 Apr 23. doi: 10.2214/AJR.25.33119.
   PubMed        
   
   

   
   Am J Pathol

4. KANEKO R, Kishimoto Y, Ishikawa O, Funahashi N, et al
   Laminin-gamma2-NR6A1 Fusion Protein Promotes Metastatic Potential in Non-Small-Cell Lung Carcinoma Cells without Epidermal Growth Factor Receptor Mutation.
   Am J Pathol. 2025 Apr 17:S0002-9440(25)00113.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

5. UEDA D, Mimae T, Kamigaichi A, Tsubokawa N, et al
   Prognostic Benefit of Segmentectomy for Patients with Low Muscle Mass in Early-Stage Lung Cancer.
   Ann Surg Oncol. 2025 Apr 24. doi: 10.1245/s10434-024-16384.
   PubMed         Abstract available
   
   

   
   Arch Bronconeumol

6. RUANO-RAVINA A, de Koning HJ
   Feasibility of Lung Cancer Screening in Europe: A Pro/con Debate.
   Arch Bronconeumol. 2025 Apr 2:S0300-2896(25)00120.
   PubMed        
   
   

   
   BMC Cancer

7. DAI L, Huang L, Li L, Tang L, et al
   Pretreatment plasma sCD14 as a prognostic indicator in advanced non-small cell lung cancer patients undergoing immunotherapy.
   BMC Cancer. 2025;25:763.
   PubMed         Abstract available
   
   
8. MINE H, Sugimoto K, Kobayashi M, Takagi H, et al
   Abnormal phosphorylation of human LRH1 at Ser510 predicts poor prognosis and promotes cell viability in lung squamous cell carcinoma.
   BMC Cancer. 2025;25:764.
   PubMed         Abstract available
   
   
9. TANG F, Cao XJ, Gong T, Huang XY, et al
   Bronchial arterial chemoembolization/infusion combined with iodine-125 brachytherapy in advanced non-small cell lung cancer: a promising salvage therapy after standard treatment failure.
   BMC Cancer. 2025;25:750.
   PubMed         Abstract available
   
   
10. HOU Y, Xue X, Zhang Z, Mai D, et al
    Genomic and clinical characterization of HER2 exon 20 mutations in non-small cell lung cancer: insights from a multicenter study in South China.
    BMC Cancer. 2025;25:752.
    PubMed         Abstract available
    
    
11. WU S, Guo Y, Wang R
    Combining network pharmacology and experimental verification to explore the inhibitory effects of Deoxyelephantopin (DET) Against Non-Small Cell Lung Cancer (NSCLC).
    BMC Cancer. 2025;25:738.
    PubMed         Abstract available
    
    
12. ZHANG X, Zhang L, Geng Z, Shang M, et al
    Potential profile analysis of financial toxicity and its related factors among lung cancer patients.
    BMC Cancer. 2025;25:740.
    PubMed         Abstract available
    
    

    
    Cancer

13. HARRIS AK, Nelson AT, Watson D, Mallinger PHR, et al
    Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries.
    Cancer. 2025;131:e35862.
    PubMed         Abstract available
    
    

    
    Chest

14. AL-ANTARY N, Hirko KA, Cassidy-Bushrow AE, Zarins KR, et al
    Coronary Artery Calcification Identified on Lung Cancer Screening CT Scans: A Scoping Review.
    Chest. 2025 Apr 18:S0012-3692(25)00437-4. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

15. ZHOU J, Muluneh B, Wang Z, Yao H, et al
    Leveraging Longitudinal Patient-Reported Outcomes Trajectories to Predict Survival in Non-Small-Cell Lung Cancer.
    Clin Cancer Res. 2025 Apr 24. doi: 10.1158/1078-0432.CCR-25-0292.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

16. ROQUET N, Beddok A, Loo M, Calais G, et al
    Post-operative hypofractionated stereotactic radiotherapy for brain metastases from lung and breast cancer in patients without prior WBRT: a retrospective dose escalation study.
    Clin Exp Metastasis. 2025;42:27.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

17. KICKEN MP, Heine RT, Azarfane I, de Rouw N, et al
    The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort Study.
    Clin Lung Cancer. 2025 Mar 26:S1525-7304(25)00056.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

18. KIM S, Ahn Y, Lee GD, Choi S, et al
    Validation of the 9th Tumor, Node, and Metastasis Staging System for Patients with Surgically Resected Non-Small Cell Lung Cancer.
    Eur J Cancer. 2025;222:115436.
    PubMed         Abstract available
    
    
19. VAN KESSEL E, Woerdman N, Pluim D, Kerklaan BM, et al
    Added prognostic value of circulating tumor cell numbers in CSF of patients with leptomeningeal metastasis from epithelial tumors.
    Eur J Cancer. 2025;220:115377.
    PubMed         Abstract available
    
    
20. GRAUS MUJE, van Diepen AE, Josemanders K, Besselink MG, et al
    Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based study.
    Eur J Cancer. 2025;220:115385.
    PubMed         Abstract available
    
    

    
    Int J Cancer

21. NALWOGA A, Jackson C, Fiorillo S, Manyeruke F, et al
    Evaluation of plasma alpha-1-antichymotrypsin as a marker for pulmonary Kaposi sarcoma.
    Int J Cancer. 2025 Jan 30. doi: 10.1002/ijc.35351.
    PubMed         Abstract available
    
    
22. WANG K, Xiang J, Zhou J, Chen C, et al
    Development and validation of a transcription factor regulatory network-based signature for individualized prognostic risk in lung adenocarcinoma.
    Int J Cancer. 2025;156:2440-2451.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

23. WANG Z, Zeng Y, Jiang H, Luo C, et al
    Management strategies for primary lung carcinosarcoma: a case study and comprehensive literature review.
    J Cancer Res Clin Oncol. 2025;151:147.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

24. GRONBERG BH, Killingberg KT, Flotten O, Bjaanaes MM, et al
    High-dose versus standard dose twice-daily thoracic radiotherapy in limited stage small-cell lung cancer: final survival data, long-term toxicity and relapse patterns in a randomised, open-label, phase II trial.
    J Thorac Oncol. 2025 Apr 19:S1556-0864(25)00696.
    PubMed         Abstract available
    
    
25. GULDBRANDSEN KF, Bloch M, Skougaard K, Ahlborn LB, et al
    Surveillance with [(18)F]FDG PET/CT of stage I-III lung cancer patients after completion of curative treatment (SUPE_R): a randomized controlled trial.
    J Thorac Oncol. 2025 Apr 19:S1556-0864(25)00693.
    PubMed         Abstract available
    
    

    
    Lung Cancer

26. SARKAR S, Choa E, Manzo LL, Richman I, et al
    Predictors and Uptake of Lung Cancer Screening in the US: An Integrative Literature Review.
    Lung Cancer. 2025;203:108529.
    PubMed         Abstract available
    
    
27. SHIRAISHI Y, Shimose T, Tobino K, Toi Y, et al
    Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002).
    Lung Cancer. 2025;203:108543.
    PubMed         Abstract available
    
    
28. BARSOUK A, Elghawy O, Watts A, Reed-Guy L, et al
    Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis.
    Lung Cancer. 2025;203:108551.
    PubMed         Abstract available
    
    
29. CHOUAID C, Bosquet L, Knott C, Li Z, et al
    Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study.
    Lung Cancer. 2025;203:108548.
    PubMed         Abstract available
    
    

    
    N Engl J Med

30. PICH O, Bernard E, Zagorulya M, Rowan A, et al
    Tumor-Infiltrating Clonal Hematopoiesis.
    N Engl J Med. 2025;392:1594-1608.
    PubMed         Abstract available
    
    

    
    Oncogene

31. WANG T, Shen Z, Yang L, Zhang X, et al
    The coagulation and tumor system are directly linked through the proteolysis and activation of epidermal growth factor receptor by thrombin.
    Oncogene. 2025;44:1153-1166.
    PubMed         Abstract available
    
    

    
    PLoS One

32. PONGPIACHAN S, Tipmanee D, Khumsup C, Hirunyatrakul P, et al
    Size-segregated analysis of PAHs in Urban air: Source apportionment and health risk assessment in an Urban canal-adjacent environment.
    PLoS One. 2025;20:e0320405.
    PubMed         Abstract available
    
    

    
    Thorax

33. KUMARASAMY C, Betts K, Norman R, McWilliams A, et al
    Future risk projection to engage 'near-miss' individuals in lung cancer screening eligibility: an analysis of ILST data.
    Thorax. 2025 Apr 24:thorax-2024-222098. doi: 10.1136/thorax-2024-222098.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.